How big is CARA Therapeutics, Inc.?

As of Jun 18, CARA Therapeutics, Inc. has a market capitalization of 234.68 million, with net sales of 7.58 million and a net profit of -45.09 million over the last four quarters. The company reported shareholder's funds of -4.59 million and total assets of 43.83 million as of Dec 24.

Market Cap: As of Jun 18, CARA Therapeutics, Inc. has a market capitalization of 234.68 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, CARA Therapeutics, Inc. reported net sales of 7.58 million and a net profit of -45.09 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -4.59 million and total assets of 43.83 million.

What does CARA Therapeutics, Inc. do?

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for pain and pruritus. As of March 2025, it has a market cap of $234.68 million, with net sales of $3 million and a net loss of $5 million.

Overview: <BR>CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 234.68 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.44 <BR>Return on Equity: 466.23% <BR>Price to Book: -29.07<BR><BR>Contact Details: <BR>Address: 4 Stamford Plz, STAMFORD CT: 06902-3834 <BR>Tel: 1 203 4063700 <BR>Fax: 1 203 5671510 <BR>Website: http://www.caratherapeutics.com/

Should I buy, sell or hold CARA Therapeutics, Inc.?

Who are in the management team of CARA Therapeutics, Inc.?

As of March 2022, CARA Therapeutics, Inc.'s management team includes Dr. Derek Chalmers as President and CEO, with Mr. Martin Vogelbaum as Lead Independent Director and several Independent Directors including Susan Shiff, Mr. Harrison Bains, Dr. Jeffrey Ives, and Mr. Christopher Posner.

As of March 2022, the management team of CARA Therapeutics, Inc. includes Dr. Derek Chalmers, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors features Mr. Martin Vogelbaum as the Lead Independent Director, along with Susan Shiff, Mr. Harrison Bains, Dr. Jeffrey Ives, and Mr. Christopher Posner, all serving as Independent Directors.

Is CARA Therapeutics, Inc. overvalued or undervalued?

CARA Therapeutics, Inc. is currently overvalued with negative valuation ratios and a risky valuation grade, despite a strong year-to-date stock performance of 111%, but its long-term outlook is concerning with a 3-year return of -89.45%.

As of 1 March 2022, CARA Therapeutics, Inc. moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its negative valuation ratios, including a Price to Book Value of -33.03, an EV to EBIT of -9.00, and an EV to EBITDA of -9.05. In comparison to its peers, CARA's EV to EBITDA ratio is significantly worse than Cyteir Therapeutics, Inc. at 0.5746 and NGM Biopharmaceuticals, Inc. at 0.1302, both of which are in a fair or risky valuation category.<BR><BR>Despite its overvaluation, CARA has shown strong recent stock performance, with a year-to-date return of 111.00%, far exceeding the S&P 500's 12.22% over the same period. However, the long-term outlook remains concerning, with a 3-year return of -89.45% compared to the S&P 500's 70.41%.

Is CARA Therapeutics, Inc. technically bullish or bearish?

As of September 4, 2025, CARA Therapeutics, Inc. shows a bullish technical trend with strong upward momentum, despite a mildly bearish KST signal, and has significantly outperformed the S&P 500 with a 1-year return of 276.26%.

As of 4 September 2025, the technical trend for CARA Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating strong upward momentum. Daily moving averages also support a bullish stance. However, the KST shows a mildly bearish signal on the weekly timeframe, which slightly tempers the overall bullish outlook. The Dow Theory and OBV are both mildly bullish on the weekly and monthly timeframes.<BR><BR>In terms of performance, CARA Therapeutics has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 276.26% compared to the S&P 500's 17.14%. Overall, the current technical stance is bullish, reflecting strong momentum despite some mixed signals in the indicators.